The global treatment market for peripheral artery disease (PAD) will expand in value from approximately $543.4 million in 2014 to a peak of $983.6 million in 2020, before falling to $816.3 million by 2024 due to the generic erosion of Brilinta and Xarelto. The initial dramatic increase in the value of the overall global PAD therapeutics space, which covers the eight major markets of the US, France, Germany, Italy, Spain, UK, Japan, and urban China, will be partly attributable to the launch of several highly promising PAD drugs currently in late-stage pipeline development. The three novel antithrombotic pharmacological agents, namely Merck & Co.’s Zontivity (vorapaxar), AstraZeneca’s Brilinta (ticagrelor), and Bayer and Janssen’s Xarelto (rivaroxaban), all have the capacity to reform the antiplatelet and anticoagulatory PAD treatment landscape. The antithrombotic agents Xarelto, Zontivity, and Brilinta will bring new drug targets and novel mechanisms of action to the arsenal of long-term blood-thinning treatment strategies.
GlobalData’s PharmaPoint: Peripheral Artery Disease – Global Drug Forecast and Market Analysis to 2024 report provides details of the peripheral artery disease (PAD) therapeutics space, with annualized market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024. Key topics covered include strategic competitor assessment, market characterization, unmet needs, pipeline analysis, clinical trial mapping and implications for the PAD therapeutics market.
Published: Oct’15 – Single user price: $10,995